21 results about "Macular oedema" patented technology

Diabetes is a disease characterized by high levels of blood glucose. It is important to keep diabetes under control to avoid short- and long-term complications. Diabetes can affect vision due to the alterations it produces in the blood vessels of the retina. This is known as Diabetic Retinopathy (DR), which is one of the leading causes of impaired vision in developed countries. One of the complications of diabetic retinopathy is Diabetic Macular Edema (DME), which is the leading cause of vision loss in diabetic patients and can appear at any stage of diabetic retinopathy. This consists of the gradual accumulation of fluid in the macula, the most important area of the retina. The determination of diabetic macular oedema is very important for the retina. The determination of diabetic macular oedema is very important for adequate treatment of this condition. A variety of technological options are used for detecting diabetic retinopathy, although only the most sophisticated detect macular oedema, a complication that appears as a consequence of diabetic retinopathy and is one of the leading causes of blindness. The invention describes a portable system for detecting diabetic macular oedema by capturing a fundus image using a portable ophthalmoscope; said image is sent via wired or wireless means to an embedded system that has an algorithm based on artificial intelligence, which extracts information from the image and processes same to identify the presence of the condition being studied.

The present invention provides a compound of Formula Iand pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention provides extracellular vesicle proteins sPTPRG and Vincin of a biomarker for detecting retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing, the difference of the expression quantity of the extracellular vesicle proteins in aqueous humor of a patient is analyzed, the protein with remarkable expression difference is screened out, the protein can be used as the biomarker for RVO-ME treatment, and the application of the biomarker for detecting the anti-VEGF treatment typing of the retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing of the RVO-ME anti-VEGF treatment typing is facilitated. Important guidance is provided for personalized treatment of RVO-ME, and the method has a wide clinical application prospect.

Pharmaceutical compositions comprising adeno-associated virus (AAV) and their use in treating diabetic macular edema are provided herein. In some aspects, treatment methods encompass co-administration of one or more corticosteroids and / or supplemental administrations of aflibercept protein.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention relates to a traditional Chinese medicine composition for treating macular edema, which is prepared from the following traditional Chinese medicines in parts by weight: 5-35 parts of astragalus mongholicus, 1-30 parts of radix rehmanniae recen, 1-30 parts of radix angelicae, 1-30 parts of rhizoma atractylodis macrocephalae and 1-30 parts of rhizoma atractylodis macrocephalae. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-30 parts of poria cocos, 1-20 parts of radix achyranthis bidentatae, 1-20 parts of moutan bark, 1-20 parts of fructus gardeniae, 1-20 parts of radix salviae miltiorrhizae, 1-20 parts of radix scrophulariae, 1-20 parts of radix ophiopogonis, 1-20 parts of radix paeoniae alba, 1-15 parts of radix curcumae, 1-10 parts of radix notoginseng and 1-10 parts of lotus leaves. The traditional Chinese medicine composition can effectively relieve macular edema after macular anterior membrane vitrectomy, has positive effects on improving the inflammatory state, microcirculation and metabolic function of a macular region of a patient, and is safe in clinical use.

Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for treating ocular diseases or conditions, including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. The compositions and methods comprise steroids and prostaglandins that exhibit anti-inflammatory activity, reduce intraocular pressure (IOP), and / or other desirable activities. Injection of the compositions in the eye provides therapeutic benefits to patients suffering from ocular conditions.

The invention provides methods, compositions, and kits containing a first therapeutic agent that is a substituted 2,3-dimethoxyquinone of Formula I, or a pharmaceutically acceptable salt thereof, for preventing the progression of diabetic retinopathy, diabetic macular edema, and / or other retinal disorders and / or other disorders.

The present disclosure relates to a method of treating diabetic macular edema in a human subject in need thereof, the method comprising (i) an induction period of topical administration of an eye drop formulation comprising 1.5% (w / v) dexamethasone to a diseased eye of the subject in a dose of 5-7 drops per day for 3, 4, 5, 6 weeks followed by (ii) a maintenance period of topical administration of an eye drop formulation comprising 1.5% (w / v) dexamethasone to a diseased eye of the subject in a dose of 5-7 drops per day. The eye drop formulation comprising 1.5% (w / v) dexamethasone is topically administered to a diseased eye of the subject at a daily dose lower than the induction period frequency (e.g., 1-3 drops).

The present invention relates to a stable liquid formulation of a fusion protein having an Fc domain of human immunoglobulin G (IgG) (in particular, a protein in which a soluble extracellular domain of a vascular endothelial growth factor (VEGF) receptor and an Fc domain of human immunoglobulin G (IgG) are fused (e.g. Aflibercept)). The present invention also relates to a composition for stabilizing a protein in which a soluble extracellular domain of a VEGF receptor and an Fc domain of IgG are fused, and a method for stabilizing a protein in which a soluble extracellular domain of a VEGF receptor and an Fc domain of IgG are fused. The present invention can promote stabilization of physiological activity through a stable liquid formulation suitable for intravitreal injection of anti-VEGF-Fc fusion proteins including Aflibercept, and improve the therapeutic effect on various ophthalmic diseases caused by abnormal angiogenesis (e.g., retinal vein occlusion, diabetic macular edema, choroidal neovascularization, and wet age-related macular degeneration, etc.).

The present invention relates to heteroarylcarboxamide compounds and their pharmaceutical uses. Specifically, the present invention relates to heteroarylcarboxamide compounds represented by general formula (I), methods for producing the same, pharmaceutical compositions containing the compound, and their use as therapeutic agents, particularly as plasma kallikrein (PKa) selective inhibitors, and in the treatment and / or prevention of diseases that may benefit from plasma kallikrein inhibition, particularly for the prevention and / or treatment of diabetic macular edema (DME), age-related macular degeneration (AMD), choroidal angiogenesis, hereditary angioedema (HAE), and post-stroke cerebral edema. JPEG2026525258000208.jpg2785

The invention provides a construction method of a retinal vein occlusion animal model, and belongs to the technical field of medicines. The method comprises the following steps of: performing eyeball surface anesthesia on an anesthetized non-human primate animal, puncturing an eyeball after disinfection to establish two sclera tunnels, respectively inserting an illumination optical fiber and an intraocular laser optical fiber into the two sclera tunnels, then injecting a photosensitizer through limb vein, immediately performing laser photocoagulation on the retinal vein under illumination of the illumination optical fiber after injection, and performing laser photocoagulation on the retinal vein under the illumination of the illumination optical fiber. And obtaining the retinal vein occlusion animal model. According to the method, the retinal vein occlusion model can be successfully constructed, secondary macular edema and vascular recanalization are carried out for a long time and can be maintained for 4-5 weeks, the manifestation sign of retinal hemorrhage after retinal vein occlusion is close to that of human beings, and the method has clinical drug responsiveness, shows the clinical research value and has good application prospects. And a good research model is provided for research in the aspects of etiology, pathology and therapeutics.

The present disclosure relates to the use of, and to methods of using, DHODH inhibitor compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions including a DHODH inhibitor compound for the treatment of ocular diseases. The ocular diseases include, but are not limited to, proliferative vitreoretinopathy, cystoid macular edema, central serous retinopathy, diabetic retinopathy, endophthalmitis, epiretinal membrane, and toxoplasmosis. The present disclosure also relates to the use of, and to methods of using, DHODH inhibitor compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions including a DHODH inhibitor compound to inhibit glial scar formation or reduce glial scar length.

The present invention provides compounds of Formula (I) and pharmaceutical compositions comprising one or more of the compounds, and methods of using the compounds to treat or prevent one or more conditions that can benefit from the inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular edema, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The application provides an extracellular vesicle protein sPTPRG, Vinculin for detecting biomarkers of anti-VEGF treatment classification of retinal vein occlusion macular edema (RVO-ME), and by analyzing differences in expression amounts of extracellular vesicle proteins in aqueous humor of patients, proteins with significant expression differences are screened out, which can be used as biomarkers for RVO-ME treatment, important guidance is provided for personalized treatment of RVO-ME, and has wide clinical application prospects.

The present invention provides compounds of Formula I and pharmaceutical compositions comprising one or more of the compounds, and methods of using the compounds to treat or prevent one or more disease states that can benefit from the inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular edema, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.